Document is current
Any future updates will be listed below
-
Authors
Püsküllüoğlu, Miroslawa https://orcid.org/0000-0002-2647-9625
Pieniążek, Małgorzata
Las-Jankowska, Manuela
Streb, Joanna
Ziobro, Marek
Pacholczak-Madej, Renata
Kilian-Van Miegem, Paulina
Rudzińska, Agnieszka
Grela-Wojewoda, Aleksandra
Łacko, Aleksandra
Jarząb, Michał
Polakiewicz-Gilowska, Anna
- License Information
-
More Information
Article History
Received: 24 July 2024
Accepted: 3 September 2024
First Online: 27 September 2024
Declarations
:
: Miroslawa Püsküllüoğlu obtained travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Elli Lilly, Janssen, Gilead and Amgen; Małgorzata Pieniążek travel grants and lecture fees from Pfizer and Novartis; lecture fees from Gilead, advisory board from Novartis; Manuela Las-Jankowska, Joanna Streb and Paulina Kilian-Van Miegem report no conflicts of interest. Marek Ziobro reports travel grants and lecture honoraria from Pierre Fabre, Novartis, Ipsen; Renata Pacholczak-Madej travel grants from Accord, GSK, BMS, lecture fees from BMS; Agnieszka Rudzińska from Gilead, BMS, Sandoz; Aleksandra Grela-Wojewoda from Novartis, BMS, Pierre Fabre, Roche, Amgen, MSD, Gilead and Pfizer, Aleksandra Łacko from Astra Zeneca, Pfizer, Novartis, Eli Lilly, Roche, Gilead Science including advisory board member role; Michał Jarząb conference fees by Gilead, Roche, speaker’s honoraria by Novartis, Roche, Lilly, Pfizer, Teva, Exact Sciences, Mammotome, advisory boards by Novartis, Pfizer; and Anna Polakiewicz-Gilowska lecture honoraria and travel grants from AstraZeneca, Roche, Novartis, Elli Lilly, Swixx, Gilead and Pfizer.
: All activities conducted in studies involving human participants adhered to the ethical guidelines set forth by the institutional ethical committee and were in accordance with the principles outlined in the 1964 Helsinki Declaration and its subsequent amendments or equivalent ethical standards. This study was approved by the Ethical Committees of the Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw Branch, Poland (reference number 21/2024, dated 22 Feb 2024) and Krakow Branch (reference number 2/2023 dated 18 April 2023). Informed consent, including standard institutional consent, was obtained from each patient before initiating SG treatment under the national reimbursement program. The Ethical Committee determined that informed consent for retrospective data collection was not required.
